Literature DB >> 32197038

Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study.

Henrik Heitmann1, Bernhard Haller2, Laura Tiemann1, Mark Mühlau1, Achim Berthele1, Thomas R Tölle1, Anke Salmen3,4, Björn Ambrosius3, Antonios Bayas5, Susanna Asseyer6, Hans-Peter Hartung7, Christoph Heesen8, Martin Stangel9, Brigitte Wildemann10, Sarah Haars11, Sergiu Groppa12, Felix Luessi12, Tania Kümpfel13, Sandra Nischwitz14, Sven G Meuth15, Luisa Klotz15, Ralf A Linker16, Uwe K Zettl17, Ulf Ziemann18, Hayrettin Tumani19,20, Björn Tackenberg21, Frauke Zipp12, Heinz Wiendl15, Ralf Gold3, Bernhard Hemmer1,22, Markus Ploner1.   

Abstract

Pain is frequent in multiple sclerosis (MS) and includes different types, with neuropathic pain (NP) being most closely related to MS pathology. However, prevalence estimates vary largely, and causal relationships between pain and biopsychosocial factors in MS are largely unknown. Longitudinal studies might help to clarify the prevalence and determinants of pain in MS. To this end, we analyzed data from 410 patients with newly diagnosed clinically isolated syndrome or relapsing-remitting MS participating in the prospective multicenter German National MS Cohort Study (NationMS) at baseline and after 4 years. Pain was assessed by self-report using the PainDETECT Questionnaire. Neuropsychiatric assessment included tests for fatigue, depression, and cognition. In addition, sociodemographic and clinical data were obtained. Prevalence of pain of any type was 40% and 36% at baseline and after 4 years, respectively, whereas prevalence of NP was 2% and 5%. Pain of any type and NP were both strongly linked to fatigue, depression, and disability. This link was even stronger after 4 years than at baseline. Moreover, changes in pain, depression, and fatigue were highly correlated without any of these symptoms preceding the others. Taken together, pain of any type seems to be much more frequent than NP in early nonprogressive MS. Moreover, the close relationship between pain, fatigue, and depression in MS should be considered for treatment decisions and future research on a possible common pathophysiology.

Entities:  

Mesh:

Year:  2020        PMID: 32197038     DOI: 10.1097/j.pain.0000000000001767

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  10 in total

1.  [Pain in multiple sclerosis and neuromyelitis optica spectrum disorders].

Authors:  Hannah L Pellkofer; Tania Kümpfel
Journal:  Schmerz       Date:  2021-05-25       Impact factor: 1.107

2.  Toll-like receptor 2 and 4 antagonism for the treatment of experimental autoimmune encephalomyelitis (EAE)-related pain.

Authors:  Andrew J Kwilasz; Suzanne M Green Fulgham; Julissa Chante Duran-Malle; Anouk E W Schrama; Eric H Mitten; Laurel S Todd; Hardik P Patel; Tracey A Larson; Madison A Clements; Kevin M Harris; Scott T Litwiler; Lewis O Harvey; Steven F Maier; Raymond A Chavez; Kenner C Rice; Anne-Marie Van Dam; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2021-01-07       Impact factor: 7.217

3.  The Problem of Pain in Systemic Lupus Erythematosus: An Explication of the Role of Biopsychosocial Mechanisms.

Authors:  Titilola Falasinnu; Cristina Drenkard; Gaobin Bao; Sean Mackey; S Sam Lim
Journal:  J Rheumatol       Date:  2020-12-01       Impact factor: 5.346

4.  The risk of polypharmacy, comorbidities and drug-drug interactions in women of childbearing age with multiple sclerosis.

Authors:  Niklas Frahm; Michael Hecker; Silvan Elias Langhorst; Pegah Mashhadiakbar; Marie-Celine Haker; Uwe Klaus Zettl
Journal:  Ther Adv Neurol Disord       Date:  2020-12-19       Impact factor: 6.570

Review 5.  Co-occurrence of Fatigue and Depression in People With Multiple Sclerosis: A Mini-Review.

Authors:  Joanna Tarasiuk; Katarzyna Kapica-Topczewska; Agata Czarnowska; Monika Chorąży; Jan Kochanowicz; Alina Kułakowska
Journal:  Front Neurol       Date:  2022-02-15       Impact factor: 4.003

Review 6.  The pathophysiology of motor fatigue and fatigability in multiple sclerosis.

Authors:  Robert Patejdl; Uwe K Zettl
Journal:  Front Neurol       Date:  2022-07-27       Impact factor: 4.086

7.  Unique features of central neuropathic pain in multiple sclerosis: Results of a cluster analysis.

Authors:  Michal Rivel; Anat Achiron; Mark Dolev; Yael Stern; Gabi Zeilig; Ruth Defrin
Journal:  Eur J Pain       Date:  2022-03-22       Impact factor: 3.651

8.  Antioxidant effect of grape seed extract corrects experimental autoimmune encephalomyelitis behavioral dysfunctions, demyelination, and glial activation.

Authors:  Maha Mabrouk; Mohamed El Ayed; Amélie Démosthènes; Youssef Aissouni; Ezzedine Aouani; Laurence Daulhac-Terrail; Meherzia Mokni; Mélina Bégou
Journal:  Front Immunol       Date:  2022-08-17       Impact factor: 8.786

9.  In-Depth Characterization of Somatic and Orofacial Sensitive Dysfunctions and Interfering-Symptoms in a Relapsing-Remitting Experimental Autoimmune Encephalomyelitis Mouse Model.

Authors:  Amélie Démosthènes; Benoît Sion; Fabrice Giraudet; Xavier Moisset; Laurence Daulhac; Alain Eschalier; Mélina Bégou
Journal:  Front Neurol       Date:  2022-01-17       Impact factor: 4.003

Review 10.  Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms.

Authors:  Henrik Heitmann; Till F M Andlauer; Thomas Korn; Mark Mühlau; Peter Henningsen; Bernhard Hemmer; Markus Ploner
Journal:  Mult Scler       Date:  2020-11-12       Impact factor: 5.855

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.